Target intelligence / Profile preview

EMG1 N1-specific pseudouridine methyltransferase (EMG1 (also known as Nep1))

Target
EMG1 (also known as Nep1)
Molecular classification
Enzyme (RNA methyltransferase), Ribosome assembly factor
01

Overview

EMG1 N1-specific pseudouridine methyltransferase (EMG1, also known as Nep1) is an essential nucleolar protein that catalyzes the N1-methylation of pseudouridine (Ψ) at a specific position in 18S ribosomal RNA (typically Ψ1248/Ψ1191 depending on species)[2][3][4]. This modification is required for the synthesis of the hypermodified nucleotide m1acp3Ψ in eukaryotic 18S rRNA, which is critical for the proper assembly and function of the small ribosomal subunit. EMG1 functions both as a methyltransferase and as an assembly factor for ribosome biogenesis, facilitating incorporation of essential ribosomal proteins into the developing subunit. Mutations in EMG1, notably Asp86Gly, lead to Bowen-Conradi syndrome, a fatal ribosomopathy, by destabilizing the protein and impairing ribosome production, which drastically reduces cell growth and division[1][4].

Other names
18S rRNA (pseudouridine(1248)-N1)-methyltransferaseNEP118S rRNA Psi1248 methyltransferaseC2F
02

Mechanism of action

Not applicable. No drugs or chemical inhibitors reported that target EMG1.

03

Biological functions

Ribosome biogenesis18S rRNA modification and maturationSmall ribosomal subunit assembly
04

Disease associations

Bowen-Conradi syndrome (autosomal recessive ribosomopathy with early lethality[1][3][4])Seckel syndrome (less clearly associated[3])Other congenital disorders linked to defective ribosome assembly
05

Safety considerations

Since EMG1 is essential for ribosome formation and cell viability, inhibition or loss leads to severe developmental disorders and cell death[1][4]. Any attempt to pharmacologically manipulate EMG1 would risk profound toxicity and lethality.
06

Biomarkers

Mutation Asp86Gly (D86G) in EMG1 is a genetic biomarker for Bowen-Conradi syndrome, especially in the Hutterite population[1][3]. No established biomarkers are used in therapeutic contexts.

Beyond the preview

Go deeper on EMG1 N1-specific pseudouridine methyltransferase (EMG1 (also known as Nep1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMG1 N1-specific pseudouridine methyltransferase (EMG1 (also known as Nep1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call